Patents by Inventor Werner Mederski

Werner Mederski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL CRYSTALLINE FORMS OF 1-(4-{[6-AMINO-5-(4-PHENOXY-PHENYL)-PYRIMIDIN-4-YLAMINO]-METHYL}-4-FLUORO-PIPERIDIN-1-YL)-PROPENONE, SALT FORMS THEREOF, AND PROCESSES TO OBTAIN
    Publication number: 20240132472
    Abstract: A solid form of 1-(4-{[6-Amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-4-fluoro-piperidin-1-yl)-propenone, or pharmaceutically acceptable salts thereof, is useful as a BTK inhibitor.
    Type: Application
    Filed: December 7, 2023
    Publication date: April 25, 2024
    Applicant: Merck Patent GmbH
    Inventors: Michael LANGE, Clemens Kuetin, Tobias Schiueter, Werner Mederski, David Maillard, Edoardo Burini
  • Crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-4-fluoro-piperidin-1-yl)-propenone, salt forms thereof, and processes to obtain
    Patent number: 11878967
    Abstract: A solid form of 1-(4-{[6-Amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methy}-4-fluoro-piperidin-1-yl)-propenone, or pharmaceutically acceptable salts thereof, is useful as a BTK inhibitor.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: January 23, 2024
    Assignee: Merck Patent GmbH
    Inventors: Michael Lange, Clemens Kuehn, Tobias Schlueter, Werner Mederski, David Maillard, Edoardo Burini
  • ARYLQUINAZOLINES
    Publication number: 20220117970
    Abstract: The invention relates to novel compounds of the formula (I) which can be used for the inhibition of serine-threonine protein kinases and for the sensitisation of cancer cells to anticancer agents and/or ionising radiation.
    Type: Application
    Filed: May 28, 2021
    Publication date: April 21, 2022
    Inventors: Thomas FUCHSS, Ulrich EMDE, Hans-Peter BUCHSTALLER, Werner MEDERSKI
  • NOVEL CRYSTALLINE FORMS OF 1-(4-{[6-AMINO-5-(4-PHENOXY-PHENYL)-PYRIMIDIN-4-YLAMINO]-METHYL}-4-FLUORO-PIPERIDIN-1-YL)-PROPENONE, SALT FORMS THEREOF, AND PROCESSES TO OBTAIN
    Publication number: 20210261525
    Abstract: A solid form of 1-(4-{[6-Amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methy}-4-fluoro-piperidin-1-yl)-propenone, or pharmaceutically acceptable salts thereof, is useful as a BTK inhibitor.
    Type: Application
    Filed: June 17, 2019
    Publication date: August 26, 2021
    Applicant: Merck Patent GmbH
    Inventors: Michael LANGE, Clemens Kuehn, Tobias Schlueter, Werner Mederski, David Maillard, Edoardo Burini
  • Arylquinazolines
    Patent number: 11065253
    Abstract: The invention relates to novel compounds of the formula (I) which can be used for the inhibition of serine-threonine protein kinases and for the sensitisation of cancer cells to anticancer agents and/or ionising radiation.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: July 20, 2021
    Assignee: MERCK PATENT GMBH
    Inventors: Thomas Fuchss, Ulrich Emde, Hans-Peter Buchstaller, Werner Mederski
  • ARYLQUINAZOLINES
    Publication number: 20200069690
    Abstract: The invention relates to novel compounds of the formula (I) which can be used for the inhibition of serine-threonine protein kinases and for the sensitisation of cancer cells to anticancer agents and/or ionising radiation.
    Type: Application
    Filed: June 26, 2019
    Publication date: March 5, 2020
    Inventors: Thomas Fuchss, Ulrich Emde, Hans-Peter Buchstaller, Werner Mederski
  • Arylquinazolines
    Patent number: 10383874
    Abstract: The invention relates to novel compounds of the formula (I) which can be used for the inhibition of serine-threonine protein kinases and for the sensitization of cancer cells to anticancer agents and/or ionizing radiation.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: August 20, 2019
    Assignee: Merk Patent GMBH
    Inventors: Thomas Fuchss, Ulrich Emde, Hans-Peter Buchstaller, Werner Mederski
  • ARYLQUINAZOLINES
    Publication number: 20190142833
    Abstract: The invention relates to novel compounds of the formula (I) which can be used for the inhibition of serine-threonine protein kinases and for the sensitisation of cancer cells to anticancer agents and/or ionising radiation.
    Type: Application
    Filed: November 13, 2018
    Publication date: May 16, 2019
    Inventors: Thomas Fuchss, Ulrich Emde, Hans-Peter Buchstaller, Werner Mederski
  • Arylquinazolines
    Patent number: 10172859
    Abstract: The invention relates to novel compounds of the formula (I) which can be used for the inhibition of serine-threonine protein kinases and for the sensitization of cancer cells to anticancer agents and/or ionizing radiation.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: January 8, 2019
    Assignee: Merck Patent GmbH
    Inventors: Thomas Fuchss, Ulrich Emde, Hans-Peter Buchstaller, Werner Mederski
  • ARYLQUINAZOLINES
    Publication number: 20170290836
    Abstract: The invention relates to novel compounds of the formula (I) which can be used for the inhibition of serine-threonine protein kinases and for the sensitisation of cancer cells to anticancer agents and/or ionising radiation.
    Type: Application
    Filed: June 26, 2017
    Publication date: October 12, 2017
    Inventors: Thomas Fuchss, Ulrich Emde, Hans-Peter Buchstaller, Werner Mederski
  • Arylquinazolines
    Patent number: 9732094
    Abstract: The invention relates to novel compounds of the formula (I) which can be used for the inhibition of serine-threonine protein kinases and for the sensitization of cancer cells to anticancer agents and/or ionizing radiation.
    Type: Grant
    Filed: May 8, 2014
    Date of Patent: August 15, 2017
    Assignee: Merck Patent GmbH
    Inventors: Thomas Fuchss, Ulrich Emde, Hans-Peter Buchstaller, Werner Mederski
  • IMIDAZO[4,5-C]QUINOLINES AS DNA-PK INHIBITORS
    Publication number: 20170166567
    Abstract: The invention relates to compounds of the formulae (I) and (II) in which R1, R2, R3, R4, R5, R8, X and m have the meaning indicated in the claims, and/or physiologically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios. The compounds of the formula (I) can be used for the inhibition of serine/threonine protein kinases and for the sensitisation of cancer cells to anticancer agents and/or ionising radiation. The invention also relates to the use of the compounds of the formula (I) in the prophylaxis, therapy or progress control of cancer, tumours, metastases or angiogenesis disorders, in combination with radiotherapy and/or an anticancer agent. The invention furthermore relates to a process for the preparation of the compounds of the formula (I).
    Type: Application
    Filed: February 27, 2017
    Publication date: June 15, 2017
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Thomas FUCHSS, Werner MEDERSKI, Frank ZENKE
  • Imidazo[4,5-C]quinolines as DNA-PK inhibitors
    Patent number: 9598408
    Abstract: The invention relates to compounds of the formulae (I) and (II) in which R1, R2, R3, R4, R5, R8, X and m have the meaning indicated in the claims, and/or physiologically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios. The compounds of the formula (I) can be used for the inhibition of serine/threonine protein kinases and for the sensitisation of cancer cells to anticancer agents and/or ionising radiation. The invention also relates to the use of the compounds of the formula (I) in the prophylaxis, therapy or progress control of cancer, tumours, metastases or angiogenesis disorders, in combination with radiotherapy and/or an anticancer agent. The invention furthermore relates to a process for the preparation of the compounds of the formula (I).
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: March 21, 2017
    Assignee: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Thomas Fuchss, Werner Mederski, Frank Zenke
  • ARYLQUINAZOLINES
    Publication number: 20160083401
    Abstract: The invention relates to novel compounds of the formula (I) which can be used for the inhibition of serine-threonine protein kinases and for the sensitisation of cancer cells to anticancer agents and/or ionising radiation.
    Type: Application
    Filed: May 8, 2014
    Publication date: March 24, 2016
    Applicant: Merck Patent GmbH
    Inventors: Thomas FUCHSS, Ulrich EMDE, Hans-Peter BUCHSTALLER, Werner MEDERSKI
  • Morpholinylbenzotriazines for use in cancer therapy
    Patent number: 9187469
    Abstract: The invention relates to compounds of the formula (I) in which R1, L and m have the meaning indicated in the claims, and/or physiologically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios. The compounds of the formula (I) can be used for the inhibition of serine/threonine protein kinases and for the sensitization of cancer cells to anticancer agents and/or ionizing radiation. The invention also relates to the use of the compounds of the formula (I) in the prophylaxis, therapy or progress control of cancer, tumors, metastases or angiogenesis disorders, in combination with radiotherapy and/or an anticancer agent. The invention furthermore relates to a process for the preparation of the compounds of the formula (I) by reaction of compounds of the formulae (II) and (III) and optionally conversion of a base or acid of the compounds of the formula (I) into a salt thereof.
    Type: Grant
    Filed: October 30, 2012
    Date of Patent: November 17, 2015
    Assignee: Merck Patent GmbH
    Inventors: Werner Mederski, Thomas Fuchss, Ulrich Emde, Hans-Peter Buchstaller
  • Morpholinylquinazolines
    Patent number: 9126952
    Abstract: The invention relates to compounds of the formulae (I), (II) and (III) in which R1, R2, R3, R4, Y, W1, W2, L, A, Alk, Cyc, Ar, Het1, Het2, Hal and n have the meaning indicated in Claim 1, and/or physiologically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios. The compounds of the formula (I) can be used for the inhibition of serine/threonine protein kinases and for the sensitization of cancer cells to anticancer agents and/or ionizing radiation. The invention also relates to the use of the compounds of the formula (I) in the prophylaxis, therapy or progress control of cancer, tumors, metastases or angiogenesis disorders, in combination with radiotherapy and/or an anticancer agent. The invention furthermore relates to a process for the preparation of the compounds of the formula (I) by reaction of compounds of the formulae (II) and (III) and optionally conversion of a base or acid of the compounds of the formula (I) into one of their salts.
    Type: Grant
    Filed: February 17, 2011
    Date of Patent: September 8, 2015
    Assignee: Merck Patent GmbH
    Inventors: Werner Mederski, Thomas Fuchss, Frank Zenke
  • IMIDAZO[4,5-C]QUINOLINES AS DNA-PK INHIBITORS
    Publication number: 20150203491
    Abstract: The invention relates to compounds of the formulae (I) and (II) in which R1, R2, R3, R4, R5, R8, X and m have the meaning indicated in the claims, and/or physiologically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios. The compounds of the formula (I) can be used for the inhibition of serine/threonine protein kinases and for the sensitisation of cancer cells to anticancer agents and/or ionising radiation. The invention also relates to the use of the compounds of the formula (I) in the prophylaxis, therapy or progress control of cancer, tumours, metastases or angiogenesis disorders, in combination with radiotherapy and/or an anticancer agent. The invention furthermore relates to a process for the preparation of the compounds of the formula (I).
    Type: Application
    Filed: April 1, 2015
    Publication date: July 23, 2015
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Thomas FUCHSS, Werner MEDERSKI, Frank ZENKE
  • Imidazo[4,5-c]quinolines as DNA-PK inhibitors
    Patent number: 9000153
    Abstract: The invention relates to compounds of the formulae (I) and (II) in which R1, R2, R3, R4, R5, R8, X and m have the meaning indicated in the claims, and/or physiologically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios. The compounds of the formula (I) can be used for the inhibition of serine/threonine protein kinases and for the sensitization of cancer cells to anticancer agents and/or ionizing radiation. The invention also relates to the use of the compounds of the formula (I) in the prophylaxis, therapy or progress control of cancer, tumors, metastases or angiogenesis disorders, in combination with radiotherapy and/or an anticancer agent. The invention furthermore relates to a process for the preparation of the compounds of the formula (I).
    Type: Grant
    Filed: July 26, 2011
    Date of Patent: April 7, 2015
    Assignee: Merck Patent GmbH
    Inventors: Thomas Fuchss, Werner Mederski, Frank Zenke
  • MORPHOLINYLBENZOTRIAZINES FOR USE IN CANCER THERAPY
    Publication number: 20140275072
    Abstract: The invention relates to compounds of the formula (I) in which R1, L and m have the meaning indicated in the claims, and/or physiologically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios. The compounds of the formula (I) can be used for the inhibition of serine/threonine protein kinases and for the sensitisation of cancer cells to anticancer agents and/or ionising radiation. The invention also relates to the use of the compounds of the formula (I) in the prophylaxis, therapy or progress control of cancer, tumours, metastases or angiogenesis disorders, in combination with radiotherapy and/or an anticancer agent. The invention furthermore relates to a process for the preparation of the compounds of the formula (I) by reaction of compounds of the formulae (II) and (III) and optionally conversion of a base or acid of the compounds of the formula (I) into a salt thereof.
    Type: Application
    Filed: October 30, 2012
    Publication date: September 18, 2014
    Applicant: Merck Patent GmbH
    Inventors: Werner Mederski, Thomas Fuchss, Ulrich Emde, Hans-Peter Buchstaller
  • Heterocyclic carbonyl compounds
    Patent number: 8815924
    Abstract: Novel heterocyclic compounds of the formula (I), in which R1, D, W, T and T? have the meanings indicated in Claim 1, are SGK inhibitors and can be used for the treatment of SGK-induced diseases and conditions, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, generally in fibroses and inflammatory processes of any type.
    Type: Grant
    Filed: April 4, 2005
    Date of Patent: August 26, 2014
    Assignee: Merck Patent GmbH
    Inventors: Dieter Dorsch, Rolf Gericke, Werner Mederski, Norbert Beier, Florian Lang